Last reviewed · How we verify
NCT05878210
Evaluating the SUBLOCADE Treatment Exit Strategy
trial in Opioid Use Disorder in 12 participants. Completed in 9 May 2025.
9 May 2025
Quick facts
| Lead sponsor | Indivior Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 12 |
| Start date | 24 November 2023 |
| Primary completion | 9 May 2025 |
| Estimated completion | 9 May 2025 |
| Sites | 2 locations across Canada, United States |
Conditions studied
- Opioid Use Disorder — all drugs for Opioid Use Disorder →
Sponsor
Indivior Inc. — full company profile →
Who can join
18 and older, any sex, with Opioid Use Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to observe and assess the successful taper and opioid withdrawal experience after participants stop receiving SUBLOCADE because their healthcare provider determines their disease symptoms have been controlled for at least 9 months and they, together with their healthcare provider, plan to discontinue MOUD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05878210
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Opioid Use Disorder
Currently open trials in the same condition.
- NCT07278518 — Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine · NA · recruiting
- NCT07044466 — Social Functioning in Opioid Use Disorder · NA · recruiting
- NCT07158853 — Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder · NA · recruiting
- NCT06943859 — Ketamine for Opioid Use Disorder · Phase 2 · recruiting
- NCT06651177 — Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder · Phase 2 · recruiting
Other Indivior Inc. trials
Trials by the same sponsor.
- NCT06576843 — INDV-6001 Multiple-Dose Pharmacokinetic Study · Phase 2 · completed
- NCT06384157 — Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder · Phase 2 · completed
- NCT05860959 — SUBLOCADE Long-term Outcomes · completed
- NCT05974046 — Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants · Phase 1 · completed
- NCT05694533 — Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05878210 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Indivior Inc.
- Last refreshed: 22 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05878210.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing